9,140 Shares in Qiagen (NYSE:QGEN) Bought by Crestline Management LP

Crestline Management LP acquired a new position in shares of Qiagen (NYSE:QGEN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,140 shares of the company's stock, valued at approximately $407,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its holdings in Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after purchasing an additional 251 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Qiagen by 3.6% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after purchasing an additional 341 shares in the last quarter. Pitcairn Co. raised its holdings in Qiagen by 5.3% during the fourth quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after purchasing an additional 354 shares in the last quarter. Headlands Technologies LLC raised its holdings in Qiagen by 2.0% during the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock worth $883,000 after purchasing an additional 397 shares in the last quarter. Finally, Moors & Cabot Inc. raised its holdings in Qiagen by 0.5% during the fourth quarter. Moors & Cabot Inc. now owns 86,474 shares of the company's stock worth $3,851,000 after purchasing an additional 426 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Stock Up 0.6%

NYSE:QGEN traded up $0.27 during trading hours on Friday, hitting $42.51. 291,298 shares of the stock traded hands, compared to its average volume of 1,143,413. The firm has a 50 day moving average price of $40.90 and a 200 day moving average price of $41.79. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The firm has a market cap of $9.45 billion, a price-to-earnings ratio of 118.47, a PEG ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same period in the previous year, the business earned $0.44 EPS. The company's revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on QGEN shares. Robert W. Baird boosted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. StockNews.com raised Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Finally, UBS Group dropped their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.